Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

MBX Capital

Investor type Venture Capital

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 26
Average round size
info
The average size of a deal this fund participated in
$14M
Portfolio companies 22
Lead investments 1
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.15
Key employees Soon
Stages of investment
Early Stage Venture

Areas of investment

  • Health Care
  • Biotechnology
  • Medical Device
  • Medical
  • Dental

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of MBX Capital:
There are no funds here. If we find new data, we will add it here.
Typical Co-investors
MBX Capital is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after MBX Capital:
There are no funds here. If we find new data, we will add it here.

Look at other 50 related and similar funds Collapse list
Fund NameLocation
AAS Technologies Hackensack, New Jersey, United States
ATPI England, London, United Kingdom
BioPort Atlantic Canada, Halifax, Nova Scotia
Chernovetskyi Investment Group -
Cordet England, London, United Kingdom
Factory LLC Bethlehem, Pennsylvania, United States
Food Angels Baden-Wurttemberg, Germany, Heilbronn
Hongjiyuan Investment China, Shanghai
ING Ventures Amsterdam, Noord-Holland, The Netherlands
Johns Hopkins Technology Ventures Baltimore, Maryland, United States
Kaleden Holdings -
Kidron New York, New York, United States
PointOne Capital Bengaluru, India, Karnataka
Seattle Seahawks Renton, United States, Washington
Stanford University Venture Fund -
Vespa Capital England, London, United Kingdom
Yoma Strategic Holdings Central Region, Singapore, Singapore

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Contraline

Biotechnology
Drug Discovery
Health Care
Medical Device
Pharmaceuticals
$7M10 Nov 2022 Virginia, United States

Freedom Biosciences

Biotechnology
Therapeutics
$10M23 Aug 2022 San Francisco, California, United States

Arine

Biotechnology
Health Care
Pharmaceutical
$29M17 Aug 2022 San Francisco, California, United States

OFFOR Health

Child Care
Dental
Electronic Health Record (EHR)
Health Care
Home Health Care
$9M13 Apr 2022 Columbus, Ohio, United States

Atlas Labs

Health Care
$40M25 Jan 2022 San Francisco, California, United States

Smiles.ai

Artificial Intelligence
Dental
Health Care
$22M23 Jan 2022 Bangalore, Karnataka, India

Contraline

Biotechnology
Drug Discovery
Health Care
Medical Device
Pharmaceuticals
$10M20 Oct 2021 Virginia, United States

Mae

Health Care
Wellness
Women's
$1M14 Sep 2021 New York, New York, United States

Attivare Therapeutics

Biotechnology
Health Care
Therapeutics
$6M17 Aug 2021 Natick, Massachusetts, United States
News
Contraline Closes $10.7 Million Series A Financing to Become a Clinical Stage Company

– Contraline, Inc. has closed $10.7m in its Series A financing.
– The financing round was led by MBX Capital, a venture capital firm that invests in early-stage healthcare and life sciences companies.
– The infusion of capital will support the initiation of a first-in-human trial of ADAM™, the world’s first hydrogel implant designed to provide long-lasting, non-permanent contraception for men.
– The ADAM hydrogel is injected into the vas deferens through a quick and minimally invasive outpatient procedure, where it’s designed to block the flow of sperm.
– This trial on ADAM is believed to be the first clinical trial on a non-hormonal male contraceptive device in over 20 years.

Maternal Health Platform Mae Launches with $1.3M

– Digital health platform, Mae, announced its $1.3M pre-seed funding round led by SteelSky Ventures.
– Other investors in this pre-seed round include Avestria Ventures, MBX Capital, Rhia Ventures.
– This list of investors represents participation from three of the most prominent venture capital funds in the women’s health space, underscoring a commitment to and belief in Mae’s innovative delivery model and its potential to drive health equity and positive outcomes for Black expectant mothers and their babies.
– Mae was founded by CEO Maya Hardigan, following 15-years in digital health product innovation, most recently at Pfizer.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent MBX Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: